Перейти к содержанию

Curis Inc (CRIS) stock: revenue, earnings & dividend

Curis Inc (CRIS, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener CRIS · Nasdaq Pharma & Biotech US-MA

Key figures

Fiscal year
2025
Revenue
9.44 m $
Revenue growth
-13.4 %
Revenue growth 5y (p.a.)
-2.7 %
Net income
-7.58 m $
Net margin
-80.3 %
Operating margin
-60.5 %
Earnings per share (diluted)
-0.58 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
20 m $
Equity
5.46 m $
Equity ratio
27.4 %
Return on equity
-138.8 %
Cash
5.06 m $
Operating cash flow
-27.2 m $
Free cash flow
–
Shares outstanding
9,512,232

History

Revenue by fiscal year

2016 7.53 m $
2017 9.9 m $
2018 10.4 m $
2019 10 m $
2020 10.8 m $
2021 10.6 m $
2022 10.2 m $
2023 10 m $
2024 10.9 m $
2025 9.44 m $

Net income by fiscal year

2016 -60.41 m $
2017 -53.32 m $
2018 -32.58 m $
2019 -32.14 m $
2020 -29.91 m $
2021 -45.44 m $
2022 -56.67 m $
2023 -47.41 m $
2024 -43.39 m $
2025 -7.58 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20259.44 m $-7.58 m $-0.58 $–-27.2 m $
202410.9 m $-43.39 m $-6.88 $–-39.56 m $
202310 m $-47.41 m $-8.96 $–-38.43 m $
202210.2 m $-56.67 m $-12.14 $–-54.34 m $
202110.6 m $-45.44 m $0.50 $–-37.62 m $
202010.8 m $-29.91 m $-0.61 $–-25.74 m $
201910 m $-32.14 m $-0.97 $–-26.21 m $
201810.4 m $-32.58 m $––-30.07 m $
20179.9 m $-53.32 m $––-48.36 m $
20167.53 m $-60.41 m $––-35.81 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)